



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents,  
Washington, D.C. 20231 on May 16, 2000

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

AMENDMENT UNDER  
37 CFR 1.825(a) THROUGH (c)  
Examining Group 1644  
Patent Application  
Docket No. SPO-103  
Serial No. 09/142,524

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : M. DiBrino, Ph.D.  
Art Unit : 1644  
Applicant(s) : Toshio Sone, Akinori Kume, Kazuo Dairiki, Akiko Iwama, Kohsuke Kino  
Serial No. : 09/142,524  
Filed : September 9, 1998  
For : Peptide-based Immunotherapeutic Agent for Treating Allergic Diseases

Box SEQUENCE

Assistant Commissioner for Patents  
Washington, D.C. 20231

AMENDMENT UNDER 37 CFR 1.825(a) THROUGH (c)

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures received in the above-identified patent application, please amend the subject application as follows:

In the Specification

Please replace pages 1-3 of the sequence listing with the accompanying sequence listing as new pages 1-5.